论文部分内容阅读
多种晚期恶性肿瘤患者常发生恶性心包积液(malignant pericardial effusion),其中以肺癌多见,约占28%~59%[1]。恶性心包积液影响患者的心肺功能,降低了患者生活、生存质量,缩短了总生存时间,并且发生恶性心包积液的患者往往预后较差,患者常因心包填塞症状加重而威胁生命。所以,应采取及时、有效地的措施处理恶性心包积液。目前,临床上通常采用心包腔内置管引流中等量以上的心包积液,
Malignant pericardial effusion often occurs in many advanced malignancies, of which lung cancer is more common, accounting for 28% to 59% [1]. Malignant pericardial effusion affects the patient’s cardiorespiratory function, reduces the patient’s life and quality of life, shortens the overall survival time, and patients with malignant pericardial effusion tend to have a poor prognosis. Patients often have life-threatening symptoms of worsening pericardial tamponade. Therefore, we should take timely and effective measures to deal with malignant pericardial effusion. Currently, the pericardial cavity is usually used in patients with pericardial drainage of the pericardial effusion,